| Abstract |
Objective Evaluate the effectiveness of metronidazole combined with clindamycin therapy in the treatment of bacterial vaginitis. Methods This study included 100 patients diagnosed with bacterial vaginitis admitted to our hospital from January 2023 to January 2024 as the analysis objects. They were randomly divided into a control group (50 cases, treated with metronidazole tablets) and an observation group (50 cases, treated with clindamycin in addition to the control group). The relevant clinical indicators, inflammatory factors (C-reactive protein, interleukin-6) levels, procalcitonin (PCT) levels, incidence of adverse reactions, and recurrence rates of the two groups of patients were compared and evaluated. Results The observation group showed significantly shorter relief of vaginal itching, recovery of vaginal discharge, and improvement of symptoms compared to the control group (P<0.05). At the same time, the levels of inflammatory markers such as C-reactive protein, interleukin-6, and procalcitonin in the observation group were also significantly lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). In addition, the recurrence rate in the observation group was significantly lower than that in the control group (P<0.05). Conclusion For patients with bacterial vaginitis, the combination therapy of metronidazole and clindamycin can achieve better therapeutic effects, significantly improve the levels of inflammatory factors and procalcitonin, and reduce the recurrence rate. It has demonstrated high value in practical applications and is worthy of clinical promotion and use.
|